Zirconium Cyclosilicate
Class: Potassium-removing Agents
Chemical Name: disodium;2,2,4,4,6,6-hexahydroxyl-1,3,5,2,4,6-trioxatrisilinane;zirconium
Molecular Formula: Na~1.5H~0.5ZrSi3O9•2–3H2O
CAS Number: 242800-27-7
Brands: Lokelma
Introduction
Nonabsorbed cation-exchange crystalline compound used for the removal of excess potassium.
Uses for Zirconium Cyclosilicate
Hyperkalemia
Treatment of hyperkalemia.
Has been shown to reduce elevated serum potassium concentrations and maintain normal serum potassium concentrations in patients with hyperkalemia.
Degree of reduction in serum potassium concentrations appears to be greater in patients with higher serum potassium concentrations at baseline.
Efficacy maintained during continued treatment for up to 1 year in clinical studies.
Not used as an emergency treatment for life-threatening hyperkalemia because of delayed onset of action.
Zirconium Cyclosilicate Dosage and Administration
Administration
Oral Administration
Administer orally as a suspension.
Administer ≥2 hours before or ≥2 hours after other oral drugs. (See Drugs that Exhibit pH-dependent Solubility under Interactions.)
Preparation of Oral Suspension
Empty entire contents of packet(s) containing sodium zirconium cyclosilicate into a glass containing approximately 45 mL of water, or more if desired. Stir thoroughly and administer immediately.
If any powder remains in glass after initial administration, add more water, stir, and administer immediately; repeat, as needed, until the entire dose is administered.
Dosage
Adults
Hyperkalemia
Oral
Initial treatment: 10 g 3 times daily for up to 48 hours.
Maintenance therapy: 10 g once daily. Monitor serum potassium concentration; dosage may be increased (in 5-g increments at intervals of ≥1 week, up to 15 g daily) or decreased, or therapy may be discontinued based on serum potassium concentration and desired target range. Usual maintenance dosage is 5 g every other day to 15 g once daily.
Prescribing Limits
Adults
Hyperkalemia
Oral
Maximum 15 g once daily for maintenance therapy.
Special Populations
Hepatic Impairment
No special dosage recommendations.
Renal Impairment
No special dosage recommendations.
Geriatric Patients
No special dosage recommendations.